Auris Medical Holding to Present at LD Micro Invitational XI Conference

Rhea-AI Summary

Auris Medical Holding Ltd. (NASDAQ: EARS) announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference on June 9, 2021, at 11:00 a.m. EST. This presentation will be webcast live, accessible through the event homepage. Auris Medical, focused on therapeutics for neurotology, rhinology, allergy, and CNS disorders, is developing intranasal betahistine for vertigo treatment and protecting against airborne viruses with its nasal spray Bentrio. The company also has two Phase 3 programs for hearing loss and tinnitus.

Hamilton, Bermuda, May 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference on Wednesday June 9, 2021, at 11:00 a.m. EST (Track 2). The event will be webcast live and available via the event homepage https://ldmicrojune2021.mysequire.com.

About Auris Medical

Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne viruses and allergens Bentrio^TM (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol “EARS.”

Investor contact:

investors@aurismedical.com   

FAQ

When will Auris Medical present at the LD Micro Invitational XI?

Auris Medical will present on June 9, 2021, at 11:00 a.m. EST.

What is the focus of Auris Medical's development?

Auris Medical focuses on therapeutics for neurotology, rhinology, allergy, and CNS disorders.

What is the status of Auris Medical's AM-125?

AM-125 is currently in Phase 2 for the treatment of vertigo.

What are the two Phase 3 programs Auris Medical is developing?

The two Phase 3 programs are Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus.

How can I watch the Auris Medical presentation live?

The presentation will be webcast live, and you can access it via the event homepage.